SG11202103801UA - Method for the treatment of myasthenia gravis - Google Patents
Method for the treatment of myasthenia gravisInfo
- Publication number
- SG11202103801UA SG11202103801UA SG11202103801UA SG11202103801UA SG11202103801UA SG 11202103801U A SG11202103801U A SG 11202103801UA SG 11202103801U A SG11202103801U A SG 11202103801UA SG 11202103801U A SG11202103801U A SG 11202103801UA SG 11202103801U A SG11202103801U A SG 11202103801UA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- myasthenia gravis
- gravis
- myasthenia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862746174P | 2018-10-16 | 2018-10-16 | |
PCT/EP2019/078093 WO2020079086A1 (fr) | 2018-10-16 | 2019-10-16 | Méthode de traitement de la myasthénie grave |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202103801UA true SG11202103801UA (en) | 2021-05-28 |
Family
ID=68290236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202103801UA SG11202103801UA (en) | 2018-10-16 | 2019-10-16 | Method for the treatment of myasthenia gravis |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220144941A1 (fr) |
EP (1) | EP3866933A1 (fr) |
JP (1) | JP7518821B2 (fr) |
KR (1) | KR20210078517A (fr) |
CN (1) | CN113646051A (fr) |
AR (1) | AR117653A1 (fr) |
AU (1) | AU2019361247A1 (fr) |
BR (1) | BR112021007092A2 (fr) |
CA (1) | CA3116091A1 (fr) |
IL (1) | IL282137A (fr) |
MA (1) | MA53903A (fr) |
MX (1) | MX2021004351A (fr) |
SG (1) | SG11202103801UA (fr) |
WO (1) | WO2020079086A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111712259A (zh) | 2017-12-13 | 2020-09-25 | 动量制药公司 | Fcrn抗体及其使用方法 |
MX2023005313A (es) * | 2020-11-06 | 2023-07-11 | Momenta Pharmaceuticals Inc | Anticuerpos fcrn y metodos de uso de estos. |
WO2023198806A1 (fr) | 2022-04-13 | 2023-10-19 | Ose Immunotherapeutics | Nouvelle classe de molécules pour la clairance sélective d'anticorps |
WO2023215587A1 (fr) * | 2022-05-05 | 2023-11-09 | UCB Biopharma SRL | Traitement de la myasthénie grave avec du zilucoplan |
TW202409086A (zh) * | 2022-06-11 | 2024-03-01 | 美商英伊布里克斯公司 | FcRn-結合多肽及其用途 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
EP0542810A1 (fr) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Procedes de production de proteines presentant une fonction souhaitee |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
GB0129105D0 (en) | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
WO2004051268A1 (fr) | 2002-12-03 | 2004-06-17 | Celltech R & D Limited | Dosage biologique permettant d'identifier des cellules productrices d'anticorps |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
PL1644412T5 (pl) | 2003-07-01 | 2019-01-31 | Ucb Biopharma Sprl | Modyfikowane fragmenty Fab przeciwciała |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
WO2005014655A2 (fr) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugues d'amidon d'hydroxyalkyle et de proteine |
GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
US20100266530A1 (en) | 2005-04-29 | 2010-10-21 | The Jackson Laboratory | FcRN ANTIBODIES AND USES THEREOF |
EP2520588A1 (fr) | 2005-08-19 | 2012-11-07 | Abbott Laboratories | Immunoglobuline à double domaine variable et ses utilisations |
EP1986690A4 (fr) | 2006-01-25 | 2009-05-13 | Univ New York State Res Found | ANTICORPS ANTI-FcRn UTILISES DANS LE TRAITEMENT D'ETATS AUTO/ALLO-IMMUNS |
GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
EP2535349A1 (fr) | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Fusions d'anticorps à double spécificité |
KR20190104432A (ko) | 2008-04-25 | 2019-09-09 | 다이액스 코포레이션 | Fcrn에 대한 항체 및 이들의 용도 |
CA2737241C (fr) | 2008-09-26 | 2017-08-29 | Ucb Pharma S.A. | Proteines de fusion d'anticorps multivalentes |
CN104367299B (zh) | 2009-07-14 | 2017-09-15 | 波技术视觉***公司 | 眼科手术测量*** |
WO2011030107A1 (fr) | 2009-09-10 | 2011-03-17 | Ucb Pharma S.A. | Anticorps multivalents |
GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
GB201208370D0 (en) * | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
GB201320066D0 (en) | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
MX2016014210A (es) | 2014-04-30 | 2017-05-01 | Hanall Biopharma Co Ltd | Anticuerpo que se une a fcrn para tratar enfermedades autoinmunes. |
GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
HRP20231399T1 (hr) | 2015-01-30 | 2024-02-16 | Momenta Pharmaceuticals, Inc. | Fcrn antitijela i načini njihove uporabe |
GB201610198D0 (en) * | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
-
2019
- 2019-10-16 WO PCT/EP2019/078093 patent/WO2020079086A1/fr unknown
- 2019-10-16 JP JP2021520958A patent/JP7518821B2/ja active Active
- 2019-10-16 CA CA3116091A patent/CA3116091A1/fr active Pending
- 2019-10-16 AR ARP190102931A patent/AR117653A1/es unknown
- 2019-10-16 EP EP19790182.0A patent/EP3866933A1/fr active Pending
- 2019-10-16 AU AU2019361247A patent/AU2019361247A1/en active Pending
- 2019-10-16 SG SG11202103801UA patent/SG11202103801UA/en unknown
- 2019-10-16 BR BR112021007092-3A patent/BR112021007092A2/pt not_active Application Discontinuation
- 2019-10-16 MA MA053903A patent/MA53903A/fr unknown
- 2019-10-16 MX MX2021004351A patent/MX2021004351A/es unknown
- 2019-10-16 US US17/286,247 patent/US20220144941A1/en active Pending
- 2019-10-16 KR KR1020217014478A patent/KR20210078517A/ko unknown
- 2019-10-16 CN CN201980077400.3A patent/CN113646051A/zh active Pending
-
2021
- 2021-04-07 IL IL282137A patent/IL282137A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210078517A (ko) | 2021-06-28 |
EP3866933A1 (fr) | 2021-08-25 |
IL282137A (en) | 2021-05-31 |
CA3116091A1 (fr) | 2020-04-23 |
MA53903A (fr) | 2021-08-25 |
JP7518821B2 (ja) | 2024-07-18 |
BR112021007092A2 (pt) | 2021-08-03 |
AR117653A1 (es) | 2021-08-25 |
CN113646051A (zh) | 2021-11-12 |
MX2021004351A (es) | 2021-05-31 |
AU2019361247A1 (en) | 2021-05-27 |
US20220144941A1 (en) | 2022-05-12 |
JP2022512713A (ja) | 2022-02-07 |
WO2020079086A1 (fr) | 2020-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL274603A (en) | Use of FCRN antagonists to treat myasthenia gravis | |
IL276917A (en) | A process for the preparation of alubixivet | |
IL282137A (en) | A method for treating severe muscle weakness | |
EP3426748A4 (fr) | Procédé d'augmentation de la masse volumique d'une saumure de traitement de puits | |
EP3463461A4 (fr) | Procédés de traitement de la myasthénie grave généralisée réfractaire | |
IL283948A (en) | Methods for treating depression | |
GB202106894D0 (en) | Process for the preparation of 3alpha-hydroxy-5#LPHA-Pregnan-20-one (brexanolone) | |
EP3894768C0 (fr) | Procédés de cryo-durcisssement | |
GB201804594D0 (en) | Bonegraft substituteand method of manufacture | |
RS64534B1 (sr) | Postupak za pripremu n-alkil-nitratoetil nitramina | |
IL281792A (en) | Treatment methods | |
GB201802839D0 (en) | Method of manufacture | |
IL281254A (en) | A process for the preparation of lanbatinib | |
IL281839A (en) | Treatment methods | |
ZA202001536B (en) | Method for the treatment of wastewaters | |
GB201815478D0 (en) | Subsea apparatus | |
IL281727A (en) | Device to create target | |
SG11202105877YA (en) | Method of treatment | |
EP3877361C0 (fr) | Procédé de préparation d'arylsulfonylpropènenitriles | |
PL3599256T3 (pl) | Sposób wytwarzania poliorganosiloksanów | |
GB201917487D0 (en) | Methods for the treatment of retinoblastoma | |
HK1254604A1 (zh) | 提高ubiad1表達的方法 | |
GB201820236D0 (en) | Method of treatment | |
GB201820157D0 (en) | Method of treatment | |
IL278861A (en) | A method for the production of halogenated N-arylpyrazoles |